Scientists

Yes, I claim that we can believe that praying works. There are a number of artefacts, let's call them traps or biases, that make it easier for us to do so. I will introduce them with the help of a joking example that serves to explain how a scientific study should be designed to be rigorous, but also to understand what limitations we should look for when reading a paper.

A study carried out in two hospitals in Denmark has compared the brain health of 120 patients admitted for covid over 18 months with that of other hospitalized patients with similar severity due to pneumonia, heart attack or need for intensive care, as well as with healthy people. The conclusions are that patients with covid worsened with respect to the latter, but did so in a similar way to other hospitalized persons. According to the authors, "although studies are needed to confirm these findings, brain health after covid-19 appears generally comparable to that of other diseases of similar severity."

For the treatment of many diseases it is necessary to use large molecules that do not resist the digestion process and must be injected. Now, a group of scientists at the Institute of Chemical Sciences and Engineering in Lausanne (Switzerland) has developed a method for synthesizing a type of protein called cyclic peptides, capable of binding to varied and complex targets, and they have done so in a way that makes them capable of being administered orally. According to the press release accompanying the publication, this opens "a new era in drug development".

A study that has analysed more than three million pregnancies with more than 130,000 miscarriages has concluded that the use of benzodiazepines during pregnancy is associated with an increased risk of miscarriage. The results are published in the journal JAMA Psychiatry.

A volcano located about four kilometres from the town of Grindavík in southwest Iceland erupted last night. The eruption follows very intense seismicity in the area last November. The Icelandic Meteorological Office (MET) reports that the eruptive fissure is about four kilometres long.

A dose of psilocybin—a hallucinogenic substance—administered to groups of 3 or 4 people suffering from cancer and depression may help reduce their depressive symptoms, according to a clinical trial conducted in the United States. The study involved 30 patients who also received individual and group therapeutic support. In another article, also published in the journal Cancer, the authors examine how the study participants perceived the therapy.

The European Medicines Agency (EMA) has recommended approval of the first drug in the European Union to use the CRISPR/Cas9 gene-editing technique. The drug, Casgevy, is indicated for the treatment of two rare inherited diseases, beta thalassaemia and sickle cell disease (sickle cell anaemia), caused by genetic mutations that affect the production or function of haemoglobin, the oxygen-carrying protein in red blood cells. Both conditions are debilitating and potentially fatal. The EMA opinion will be sent to the European Commission for a decision on an EU-wide marketing authorisation.

The largest meta-analysis to date that studies the risk of children of people with a mental disorder also suffering from some type of mental disorder during their lifetime has been published, with Spanish participation. According to the study, the risk is more than double that of the rest of the population. To explain the study and resolve any doubts that may arise, the Science Media Centre Spain organised an information session with one of the authors, psychiatrist Joaquim Raduà.

In the year 2023, Science magazine has chosen the development and discovery that GLP-1 medications, agonists of the glucagon-like peptide-1, can mitigate health issues associated with obesity as the most important scientific breakthrough. Similarly, Nature magazine has selected biochemist Svetlana Mojsov, a key figure in the discovery of GLP-1, as one of the top ten scientists of the year.